CN113491700B - 牛磺罗定在抗病毒中的应用 - Google Patents

牛磺罗定在抗病毒中的应用 Download PDF

Info

Publication number
CN113491700B
CN113491700B CN202110752333.XA CN202110752333A CN113491700B CN 113491700 B CN113491700 B CN 113491700B CN 202110752333 A CN202110752333 A CN 202110752333A CN 113491700 B CN113491700 B CN 113491700B
Authority
CN
China
Prior art keywords
taurolidine
virus
cells
mice
trd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110752333.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113491700A (zh
Inventor
高玉伟
苏忠
李元果
李松
吕朝相
王铁成
钟武
向海洋
周彤
孙伟洋
王雪峰
周博
李恩涛
冯娜
赵永坤
杨松涛
夏咸柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Changchun Mailing Bioengineering Co ltd
Military Veterinary Research Institute Academy Of Military Medical Sciences
Original Assignee
Changchun Mailing Bioengineering Co ltd
Military Veterinary Research Institute Academy Of Military Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010638926.9A external-priority patent/CN111658652A/zh
Priority claimed from CN202010639186.0A external-priority patent/CN111773227A/zh
Priority claimed from CN202010994928.1A external-priority patent/CN112641789A/zh
Application filed by Changchun Mailing Bioengineering Co ltd, Military Veterinary Research Institute Academy Of Military Medical Sciences filed Critical Changchun Mailing Bioengineering Co ltd
Publication of CN113491700A publication Critical patent/CN113491700A/zh
Application granted granted Critical
Publication of CN113491700B publication Critical patent/CN113491700B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110752333.XA 2020-07-06 2021-07-02 牛磺罗定在抗病毒中的应用 Active CN113491700B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN2020106389269 2020-07-06
CN202010638926.9A CN111658652A (zh) 2020-07-06 2020-07-06 牛磺罗定在制备抗冠状病毒药物中的应用
CN2020106391860 2020-07-06
CN202010639186.0A CN111773227A (zh) 2020-07-06 2020-07-06 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用
CN202010994928.1A CN112641789A (zh) 2020-09-21 2020-09-21 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
CN2020109949281 2020-09-21

Publications (2)

Publication Number Publication Date
CN113491700A CN113491700A (zh) 2021-10-12
CN113491700B true CN113491700B (zh) 2023-03-28

Family

ID=77998103

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110752333.XA Active CN113491700B (zh) 2020-07-06 2021-07-02 牛磺罗定在抗病毒中的应用

Country Status (4)

Country Link
JP (1) JP7752675B2 (enExample)
CN (1) CN113491700B (enExample)
BR (1) BR112023000308A2 (enExample)
WO (1) WO2022007713A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917285B (zh) * 2022-04-06 2023-06-23 军事科学院军事医学研究院军事兽医研究所 一种多糖化合物在预防和治疗呼吸道病毒感染药物中的应用
CN115350181B (zh) * 2022-08-17 2023-12-29 吉林大学 一种小分子化合物在制备抗病毒感染的药物中的应用
CN117503777A (zh) * 2023-03-17 2024-02-06 中国人民解放军军事科学院军事医学研究院 化合物在抗病毒中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699572A1 (en) * 2011-04-21 2014-02-26 Origenis GmbH Heterocyclic compounds as kinase inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608051B1 (en) * 1999-03-12 2003-08-19 Medpointe Healthcare Inc. Compositions and methods for treating blood
US6302108B1 (en) * 2000-03-10 2001-10-16 Carter-Wallace, Inc Spermicidal and viricidal compositions
DE102011077393A1 (de) * 2011-06-10 2012-12-13 Johannes Reinmüller Antiinfektives Mittel
US9241943B2 (en) * 2012-06-18 2016-01-26 Geistlich Pharma Ag Oxathiazine derivatives as antibacterial and anticancer agents
SMT202200091T1 (it) * 2014-12-19 2022-03-21 Geistlich Pharma Ag Processi per preparare composti simili a ossatiazina
CA2999973A1 (en) * 2015-08-31 2017-03-09 Cormedix Inc. Delivery of active agents using nanofiber webs
CN112641789A (zh) * 2020-09-21 2021-04-13 军事科学院军事医学研究院军事兽医研究所 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
CN111617086A (zh) * 2020-07-06 2020-09-04 长春迈灵生物工程有限公司 牛磺罗定在制备抗hpv病毒药物中的应用
CN111773227A (zh) * 2020-07-06 2020-10-16 长春迈灵生物工程有限公司 牛磺罗定在制备抗新型冠状病毒SARS-CoV-2药物中的应用
CN111658652A (zh) * 2020-07-06 2020-09-15 长春迈灵生物工程有限公司 牛磺罗定在制备抗冠状病毒药物中的应用
CN111671758A (zh) * 2020-07-06 2020-09-18 长春迈灵生物工程有限公司 牛磺罗定在制备抗hiv病毒药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2699572A1 (en) * 2011-04-21 2014-02-26 Origenis GmbH Heterocyclic compounds as kinase inhibitors

Also Published As

Publication number Publication date
JP7752675B2 (ja) 2025-10-10
WO2022007713A1 (zh) 2022-01-13
JP2023533041A (ja) 2023-08-01
BR112023000308A2 (pt) 2023-03-28
CN113491700A (zh) 2021-10-12

Similar Documents

Publication Publication Date Title
CN110325187A (zh) 治疗流感的方法
JP7752675B2 (ja) ウイルスに対するタウロリジンの使用
EA035439B1 (ru) Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний
KR20200069381A (ko) 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법
CN106668002A (zh) 芦竹碱及其衍生物在制备抗7型腺病毒药物中的应用
CN112546038A (zh) 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN112641789A (zh) 一种化合物在治疗和预防新型冠状病毒和流感病毒药物方面的应用
US11433080B2 (en) Antiviral treatment
CN113101283B (zh) 一种多苯环共轭分子在制备抗病毒药物中的用途及抗病毒药物
CN112843043A (zh) 盐霉素在制备抗冠状病毒药物中的应用
CN117510409B (zh) 广谱抗病毒中药单体蝙蝠葛苏林碱、及其药物组合物和应用
CN113893345A (zh) 247种化合物及其组合物在抗新型冠状病毒感染中的应用
CN101461805B (zh) 一种抗汉坦病毒药物阿比朵尔的用途
CN116585317A (zh) 石蒜碱β-芳基丙烯酸酯衍生物在制备抗病毒药物中的应用
CN113350482A (zh) 植物凝集素pha-e在制备治疗冠状病毒所致疾病的药物中的应用
CN117503777A (zh) 化合物在抗病毒中的应用
CN113197912B (zh) 异戊酰螺旋霉素类化合物及其组合物在制备抗病毒药物中的应用
CN115957222B (zh) Efavirenz在制备抗腺病毒ADV7药物中的应用
WO2021164672A1 (zh) 抗rna病毒药物及其应用
CN112315959A (zh) 卟啉类化合物在制备抗冠状病毒药物中的应用
CN115400121B (zh) 一种snx-2112在制备用于抗腺病毒感染的药物中的用途
CN116139155B (zh) 黎芦碱及黎芦提取物在制备抗病毒药物中的应用
CN117503776A (zh) 一种药物组合物及其用途
CN117064893A (zh) 阿美替尼在制备抗冠状病毒药物中的应用
CN120131608A (zh) 溴酚-苯甲酰胺类化合物作为3CLpro和PLpro双靶点抑制剂在治疗猪流行性腹泻病毒疾病中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant